<DOC>
	<DOCNO>NCT02788656</DOCNO>
	<brief_summary>This pilot study assess impact sacubitril/valsartan ( trade name Entresto ) elevate pulmonary artery pressure patient heart failure reduce ejection fraction , measure use previously implant hemodynamic monitoring device ( CardioMEMS ) .</brief_summary>
	<brief_title>Pulmonary Artery Pressure Reduction With ENTresto ( Sacubitril/Valsartan )</brief_title>
	<detailed_description>Angiotensin-converting enzyme inhibitor ( ACEi ) cornerstone treatment patient heart failure reduce ejection fraction ( HFrEF ) 25 year . They include every major set guideline HFrEF management . Angiotensin receptor blocker ( ARB 's , valsartan ) similarly show decrease mortality rate patient HFrEF patient unable tolerate ACEi therapy . The new neurohormonal therapy approve heart failure ( August 2015 ) sacubitril/valsartan ( trade name Entresto ) . This medication first new family agent ( ARNI = angiotensin receptor antagonist neprilysin inhibitor ) , combine approve angiotensin receptor blocker valsartan sacubitril , inhibitor neprilysin , neutral endopeptidase degrade endogenous vasoactive peptide . Treatment sacubitril increase circulate level natriuretic peptide , show facilitate natriuresis vasodilation . Although precise mechanism responsible benefit heart failure remain unclear , sacubitril/valsartan may reduce fluid retention vasoconstriction contribute heart failure symptom , may also decrease apoptosis remodel lead disease progression . There limited data incremental acute long-term hemodynamic effect composite neprilysin/angiotensin-receptor inhibitor enalapril , data may provide important mechanistic insight . Progress HF management outside hospital include validation strategy ongoing monitoring pulmonary artery pressure every day home via monitor implanted distal pulmonary artery , CardioMEMS device . The information transmit website review HF team , intervene adjust diuretic medication phone avert decompensation re-hospitalization . The device receive FDA approval mid 2014 , implant many cardiac catheterization laboratory , include Brigham Women 's Hospital . The pressure information review regularly HF management team regular contact patient aid management decision . In summary , pilot study assess impact sacubitril/valsartan , approve drug heart failure reduce ejection fraction ( HFrEF ) elevate pulmonary artery pressure measure use implanted monitoring device also approve patient . Both medication device use accord approved indication .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<criteria>1 . Patients able provide write informed consent 2 . Patients â‰¥18 year age , male female , NYHA Class II III HF , previously hospitalize HFrEF LVEF &lt; 35 % ( measure within past year ) , subsequent LVEF &gt; 35 % . 3 . Systolic BP &gt; 95 mm Hg recent clinical assessment . 4 . Stable , ambulatory patient without need change diuretic HF drug ( RAS blocker , beta blocker mineralocorticoid receptor blocker ) past 5 day 5 . CardioMEMS HF System implant NYHA Class III HF . Patient transmit information regularly system function appropriately . 6 . NTproBNP &gt; 500 pg/ml within 90 day CardioMEMS implantation . 7 . Average PAPm &gt; 20mm Hg 7 day prior enrollment , include least 4 daily measurement . 8 . Women childbearing age must highly effective method contraception 1 . Treatment vasodilator ( nitrate , hydralazine ) and/or IV inotropic drug . 2 . Entresto take within past 30 day . 3 . History hypersensitivity , intolerance angioedema previous reninangiotensin system ( RAS ) blocker , ACE inhibitor , ARB , Entresto . 4. eGFR &lt; 30 ml/min/1.73 m2 measure simplified MDRD formula . 5 . Serum potassium &gt; 5.5 mmol/L . 6 . Acute coronary syndrome , stroke , transient ischemic attack , cardiovascular surgery , PCI , carotid angioplasty within precede 3 month . 7 . Coronary carotid artery disease likely require surgical percutaneous intervention within 3 month trial entry . 8 . Noncardiac condition ( ) primary cause dyspnea . 9 . Implantation cardiac resynchronization therapy device ( CRT/D ) within pr precede 3 month intent implant CRT/D , may alter pressure course study . 10 . History heart transplantation , placement LVAD , list Status IA cardiac transplantation plan placement LVAD within 3 month follow randomization . 11 . Documented untreated ventricular arrhythmia syncopal episode within prior 3 month . 12 . Symptomatic bradycardia second third degree heart block without pacemaker . 13 . Hepatic dysfunction , evidence total bilirubin &gt; 3 mg/dl . 14 . Pregnancy 15 . Women breastfeed 16 . Chronic lithium use</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>heart failure</keyword>
	<keyword>neprilysin</keyword>
	<keyword>implantable hemodynamic monitor</keyword>
	<keyword>angiotensin-receptor blocker</keyword>
	<keyword>angiotensin-converting enzyme inhibitor</keyword>
</DOC>